A Case of Multisystem Inflammatory Syndrome in a 12-Year-old Male After COVID-19 mRNA Vaccine

Pediatr Infect Dis J. 2022 Mar 1;41(3):e87-e89. doi: 10.1097/INF.0000000000003432.

Abstract

The pathophysiology of multisystem inflammatory syndrome (MIS) in children (MIS-C) is unknown. It occurs several weeks after COVID-19 infection or exposure; however, MIS is rarely reported after COVID-19 vaccination, and cases are mostly in adults. Herein, we present a 12-year-old male who had no prior COVID-19 infection or exposure and developed MIS-C after his first dose of COVID-19 mRNA vaccine.

Publication types

  • Case Reports

MeSH terms

  • COVID-19 / complications*
  • COVID-19 / diagnosis
  • COVID-19 / etiology
  • COVID-19 / prevention & control
  • COVID-19 Drug Treatment
  • COVID-19 Vaccines / adverse effects*
  • Child
  • Diagnosis, Differential
  • Drug Therapy, Combination
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Male
  • Methylprednisolone / therapeutic use
  • SARS-CoV-2
  • Systemic Inflammatory Response Syndrome / diagnosis
  • Systemic Inflammatory Response Syndrome / drug therapy
  • Systemic Inflammatory Response Syndrome / etiology*
  • Vaccines, Synthetic / adverse effects*
  • mRNA Vaccines / adverse effects*

Substances

  • COVID-19 Vaccines
  • Glucocorticoids
  • Immunoglobulins, Intravenous
  • Vaccines, Synthetic
  • mRNA Vaccine
  • mRNA Vaccines
  • Methylprednisolone

Supplementary concepts

  • pediatric multisystem inflammatory disease, COVID-19 related